Full Press Release Details
Announces Reverse Stock Split
HOUSTON, TX (July 18, 2025) - CNS Pharmaceuticals,
Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development
of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-12 reverse split
of its common stock. Beginning on July 22, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market
("Nasdaq") on a split adjusted basis under the trading symbol "CNSP" but will trade under the following new CUSIP
As a result of the reverse stock split, every
12 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.
Outstanding warrants, equity-based awards and other outstanding equity rights will be proportionately adjusted by dividing the shares
of common stock underlying the securities by 12 and multiplying the exercise/conversion price, as the case may be, by 12. No fractional
shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share
because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead,
each stockholder will be entitled to receive a cash payment in lieu of a fractional share. The par value of the common stock will remain
unchanged at $0.001 per share after the reverse split. The number of authorized shares of common stock will be proportionately reduced
to 25 million shares. The reverse split affects all stockholders uniformly and will not alter any stockholder's percentage interest
in the Company's equity, except to the extent that the reverse split results in some stockholders owning a fractional share as described
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical
company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central
The Company's drug candidate TPI 287 is an abeotaxane,
which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest
TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in
clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including
recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic
melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability
For more information, please visit www.CNSPharma.com,
and connect with the Company on X, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in
this press release include, without limitation, the timing and completion of the reverse split. These statements relate to future events,
future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable
as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking
statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately''
or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk
Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from
time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release
to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Relations Contact